XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) will consolidate its American Depositary Shares (ADSs) from one ADS to 400 ordinary shares, a 1‑for‑4 reverse split that will take effect on March 25, 2026. The company says the change will not alter the underlying ordinary shares and that the ADSs will continue to trade under the ticker “XTLB” on the Nasdaq Capital Market. No fees will be charged to ADS holders, and fractional entitlements will be aggregated and sold by the depositary bank, with proceeds distributed to holders.
The reverse split is a direct response to Nasdaq’s continued‑listing requirements. XTLB received a notice on January 20, 2026 that its stockholders’ equity of $2,453,000 fell short of the $2,500,000 minimum by $47,000. A separate notice on December 22, 2025 indicated that the company’s closing bid price had been below $1 per share for 30 consecutive business days. By raising the per‑share price through a reverse split, XTLB aims to meet the bid‑price threshold and avoid a potential delisting.
In addition to the Nasdaq compliance issues, XTLB’s subsidiary, The Social Proxy Ltd., has entered court‑ordered liquidation after being declared insolvent. The company has also been identified as a “public shell” under Nasdaq Listing Rule 5101, a designation that further underscores its precarious position. These developments highlight the financial fragility that the reverse split seeks to mitigate.
XTLB has a history of reverse splits, including a 1:4 split on December 24, 2025, and earlier splits in 2017, 2012, and 2009. The company describes itself as an IP portfolio holder, licensing hCDR1 technology for lupus and Sjögren’s syndrome. The reverse split is part of a broader strategy to strengthen the company’s balance sheet and maintain market presence while it pursues new opportunities.
Management has announced plans to acquire 85 % of NeuroNOS from Beyond Air and to seek a private placement to fund the transaction. The acquisition is intended to address Nasdaq Listing Rule 5550(b)(1) deficiencies and to provide a clearer path to compliance. XTLB has also filed an appeal against the delisting notice, indicating that it is actively working to retain its Nasdaq listing status.
The reverse split, while a routine corporate action, carries significant implications for investors. It signals ongoing compliance challenges and a need for liquidity improvement. The company’s ability to meet Nasdaq’s equity and bid‑price requirements will be closely watched, and the liquidation of its subsidiary adds further risk to the firm’s financial outlook. Investors should consider these factors when evaluating XTLB’s future prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.